^
    1d
    GS-US-742-7757: Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas (2025-524095-27-00)
    P1/2, N=45, Not yet recruiting, Gilead Sciences Inc.
    New P1/2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18)
    |
    PD-L1 expression • HER-2 negative
    |
    Opdivo (nivolumab) • albumin-bound paclitaxel • Cyramza (ramucirumab) • denikitug (GS-1811)
    2d
    REVIVE: A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=39, Recruiting, University of Chicago | Not yet recruiting --> Recruiting
    Enrollment open • Checkpoint inhibition
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • Imfinzi (durvalumab) • gemcitabine • docetaxel • Cyramza (ramucirumab) • Libtayo (cemiplimab-rwlc)
    4d
    GS-US-742-7757: Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas (2025-524095-27-00)
    P1/2, N=26, Not yet recruiting, Gilead Sciences Inc.
    New P1/2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18)
    |
    PD-L1 expression • HER-2 negative
    |
    Opdivo (nivolumab) • albumin-bound paclitaxel • Cyramza (ramucirumab) • denikitug (GS-1811)
    8d
    Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance (clinicaltrials.gov)
    P2, N=59, Recruiting, Abramson Cancer Center at Penn Medicine | Trial completion date: Apr 2026 --> Sep 2026 | Trial primary completion date: Apr 2026 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • Cyramza (ramucirumab) • pemetrexed
    8d
    Plasma PlGF as a Potential Biomarker in Ramucirumab-Based Second-Line Therapy for Advanced Gastroesophageal Adenocarcinoma: Exploratory Biomarker Analysis from the Phase II Part of the RAMIRIS Trial. (PubMed, Int J Cancer)
    The phase II RAMIRIS trial compared RAM plus paclitaxel with RAM plus FOLFIRI (5-fluororuracil, leucovorin and irinotecan) in this setting...Elevated PlGF-particularly its early increase during RAM-based therapy-was associated with shortened survival and may represent a dynamic marker of unfavorable prognosis in advanced gastric/GEJ adenocarcinoma. Given the exploratory nature of this analysis, these findings should be considered hypothesis-generating and require validation in independent biomarker-driven studies.
    P2 data • Journal
    |
    CA9 (Carbonic anhydrase 9)
    |
    paclitaxel • 5-fluorouracil • Cyramza (ramucirumab) • irinotecan • leucovorin calcium
    13d
    Pembrolizumab Plus Ramucirumab in Metastatic Gastric Cancer (clinicaltrials.gov)
    P2, N=26, Completed, Samsung Medical Center | Recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Cyramza (ramucirumab)
    13d
    Impact of prior nivolumab on treatment outcomes of taxane plus ramucirumab in advanced gastric cancer. (PubMed, Jpn J Clin Oncol)
    Prior ICI exposure may not significantly affect the efficacy or safety of subsequent taxane plus RAM therapy.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Opdivo (nivolumab) • Cyramza (ramucirumab) • oxaliplatin
    15d
    Lung-MAP Sub-Study: Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial) (clinicaltrials.gov)
    P2, N=66, Recruiting, SWOG Cancer Research Network | Trial completion date: May 2027 --> Jun 2028 | Trial primary completion date: May 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • MET amplification
    |
    Tagrisso (osimertinib) • Cyramza (ramucirumab) • Tabrecta (capmatinib)
    15d
    Acclaim-2: Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer (clinicaltrials.gov)
    P1, N=5, Terminated, Genprex, Inc. | Phase classification: P1/2 --> P1
    Phase classification
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    ALK mutation
    |
    Keytruda (pembrolizumab) • docetaxel • Cyramza (ramucirumab) • Reqorsa (quaratusugene ozeplasmid)
    22d
    CLARITY-Gastric 01: AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 (clinicaltrials.gov)
    P3, N=592, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 expression • CLDN18.2 positive • CLDN1 positive
    |
    paclitaxel • docetaxel • AiTan (rivoceranib) • Cyramza (ramucirumab) • irinotecan • Lonsurf (trifluridine/tipiracil) • sonesitatug vedotin (AZD0901)
    24d
    A Case of Recurrent Esophagogastric Junction Cancer with Long‒Term Complete Response by Trastuzumab Deruxtecan (PubMed, Gan To Kagaku Ryoho)
    After neoadjuvant chemotherapy (docetaxel +oxaliplatin + S-1: DOS), he underwent proximal gastrectomy, double tract reconstruction and para-aortic lymph node dissection...In November 2021, the patient presented with para-aortic lymph node recurrence and was treated with S-1 + oxaliplatin (SOX) + trastuzumab (Tmab) and paclitaxel + ramucirumab, but the lymph nodes were enlarged and trastuzumab deruxtecan (T-DXd) therapy was started...T-DXd was approved for the treatment of HER2-positive unresectable advanced or recurrent gastric cancer from the 6th edition of Gastric Cancer Treatment Guidelines. We report a case of long-term CR maintenance after T-DXd therapy for recurrent esophagogastric junction gastric cancer.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    paclitaxel • docetaxel • Enhertu (fam-trastuzumab deruxtecan-nxki) • Cyramza (ramucirumab) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)
    27d
    REVIVE: A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=39, Not yet recruiting, University of Chicago
    New P2 trial • Checkpoint inhibition
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • Imfinzi (durvalumab) • gemcitabine • docetaxel • Cyramza (ramucirumab) • Libtayo (cemiplimab-rwlc)